- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07023601
- Original Trial
International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva. (VULCA-NODE)
June 9, 2025 updated by: Myriam Gracia, Hospital Universitario La Paz
Sentinel Node Biopsy in Relapsed Vulvar Cancer. VULCA-NODE Study.
Acronym: VULCA-NODE Study Title: Sentinel Node Biopsy in Relapsed Vulvar Cancer Primary Objetive: To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting.
Secondary Objetives:
- To compare the utility of different tracers in the detection of SLN for recurrent disease and the injection pattern.
- To evaluate the surgical complications rate.
- To analyze the nodal status by ultrastaging .
- To assess the disease free and overall survival at 24 months from the first recurrence, as well as the dissemination pattern after the procedure.
Study Design: International prospective multicentre study
Inclusion Criteria:
- First local recurrent squamous cell carcinoma of the vulva (SCC).
- Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus.
- No distant or groin metastasis.
- To be able to understand the study and sign informed consent.
- Over 18 years old.
- To be able to undergo planned follow up.
Exclusion Criteria:
- Multifocal recurrent disease of the vulva.
- Previous bilateral IFL.
- Synchronous, non-curable second malignancy. Timing: 4 years
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Madrid, Spain, 28046
- La Paz University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- First local recurrent squamous cell carcinoma of the vulva (SCC).
- Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus.
- No distant or groin metastasis.
- To be able to understand the study and sign informed consent.
- Over 18 years old.
- To be able to undergo planned follow up.
Exclusion Criteria:
- Multifocal recurrent disease of the vulva.
- Previous bilateral IFL.
- Synchronous, non-curable second malignancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: First local recurrent vulvar carcinoma
|
All patients will undergo a local tumor radical excision and unilateral (if medial border > 1 cm from midline) or bilateral (medial border < or equal to 1 cm from midline) Sentinel Lymph Node procedure, followed by bilateral Inguinophemoral lymphadenectomy. .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting.
Time Frame: From enrollment to the first 30 day after surgery
|
From enrollment to the first 30 day after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2025
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2029
Study Registration Dates
First Submitted
June 9, 2025
First Submitted That Met QC Criteria
June 9, 2025
First Posted (Actual)
June 17, 2025
Study Record Updates
Last Update Posted (Actual)
June 17, 2025
Last Update Submitted That Met QC Criteria
June 9, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Genital Diseases, Female
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Vulvar Diseases
- Carcinoma
- Vulvar Neoplasms
Other Study ID Numbers
- HULP: PI-6605
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.